In the October 2016 issue of European Pharmaceutical Review, Andrew Butcher writes about the emergence of value-based pricing, where the price is determined as a function of measurable “value” brought by the product to relevant stakeholders. He discusses the challenges of measuring value in complex health systems and the importance of understanding the market and engaging a wide group of stakeholders well before a product launches. To read the article, click the link below.
Life sciences considerations for investment treaty disputes
Greg Bell, Andrew Tepperman, and Justin Ho co-authored a chapter in the ninth edition of The Investment Treaty Arbitration Review. The chapter titled...